A novel program for treating patients with trimorbidity
Authors:
- Sanjeev SockalingamSanjeev Sockalingam
- Diana BlankDBDiana Blank
- Claire Ann BangaCBClaire Ann Banga
- Kate MasonKMKate Mason
- Zoë DoddZDZoë Dodd
- Jeff PowisJPJeff Powis
- 1 December 2013
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 25 (12) , 1377-1384
Abstract
Advances in hepatitis C virus (HCV) treatment have yielded improved virological response rates, and yet, many individuals with psychiatric illness still fail to receive HCV therapy. Concerns about safety, adherence, and efficacy of HCV treatment are compounded and treatment is further deferred when substance use is also present. This is especially problematic given the disproportionately high rates of both mental health issues and substance use among individuals living with HCV. This study sought to examine HCV treatment outcomes in clients with serious mental illness (SMI) and with high rates of active substance use who were participating in a community-based HCV treatment program. A retrospective chart review of 129 clients was carried out. Patients were classified as having an SMI if they had a history of bipolar disorder, psychotic disorder, past suicide attempt or mental health related hospitalization. Fifty-one patients were defined as having an SMI. Among the 46 patients with SMI and a detectable HCV viral load, HCV antiviral therapy was initiated in nine (19.6%). A relapse or an increase in substance use was common (77.8% or n=7), as was the requirement for adjustment or initiation of psychotropic medications (66.7% or n=6) during HCV antiviral therapy. Despite these barriers, rates of adherence to antiviral therapy were high and overall sustained virological response rates were comparable with published trials. This study is the first to report HCV treatment outcomes in a population in which SMI and active polysubstance use was prevalent and suggests that with appropriate models of care, clients with trimorbidity can be treated safely and effectively.Keywords
This publication has 20 references indexed in Scilit:
- Screening inventories to detect depression in chronic hepatitis C patientsGeneral Hospital Psychiatry, 2012
- A Comparison of Depression Screening Instruments in Hepatitis C and the Impact of Depression on Somatic SymptomsPsychosomatics, 2011
- Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical updateJournal of Viral Hepatitis, 2010
- Risk factors for fatal and nonfatal repetition of suicide attempt: a critical appraisalCurrent Opinion in Psychiatry, 2010
- Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residentsJournal of Viral Hepatitis, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Persistent Psychosis After Treatment With Interferon AlfaJournal of Clinical Psychopharmacology, 2006
- Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric IllnessPsychiatric Services, 2006
- Prevalence of Hepatitis A, Hepatitis B, and HIV Among Hepatitis C–Seropositive State Hospital PatientsThe Journal of Clinical Psychiatry, 2003
- A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferonJournal of Hepatology, 1996